Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

Inclusion Criteria:

* Woman with a history of breast cancer, stage 0, I, II, or III
* At least 12 months from definitive surgical procedure (i.e. lumpectomy or mastectomy)
* At least 3 months from completion of chemotherapy
* Postmenopausal, defined as no menstrual cycle for 12 consecutive months, or surgical menopause
* Have one or more stated symptoms of atrophic vaginitis, such as vaginal dryness, genital irritation/itching, genital pain, and/or dyspareunia
* No current use of estrogen replacement therapy
* If recent use of estrogen replacement therapy, off at least three months
* No current use of estradiol-releasing vaginal ring or estradiol vaginal tablets; if recent use of these products, off at least 3 consecutive months
* No evidence of disease (NED), any cancer other than breast cancer
* No current use of oral omega 3 fatty acids or Vitamin E; if recent consistent use of these products, off at least six months; if sporadic use of these products, off at least 3 consecutive months
* May be taking oral anti-estrogens or aromatase inhibitors, and/or biologic therapy
* Must be willing to undergo venipuncture at 0, 3, and 6 months
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* No history of a bleeding tendency
* No history of uncontrolled hypertension, heart disease or stroke
* Hemoglobin \> 10 g/dL
* Hematocrit \> 30%
* White blood count \> 3.5 K/uL
* Platelet count \> 100,000/mm\^3
* Fasting serum glucose \< 115 mg/dL
* Total bilirubin \< 1.6 mg/dL
* Transaminases alanine aminotransferase(ALT)and aspartate aminotransferase (AST)\< 1.5 x ULN (upper limit of normal)

Exclusion Criteria:

* Metastatic malignancy of any kind
* Ongoing chemotherapy or radiation therapy (ongoing hormonal therapy and/or biologic therapy are allowed)
* History of pelvic or genital radiation therapy
* Use of Coumadin or other anticoagulants
* Known, active pelvic, vaginal, or urinary tract infections
* Current use of hormone replacement therapy, either systemic or local
* Uncontrolled co-morbidities including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable hypertension
* Psychiatric illness/social situation that would limit adherence to study requirements
* Consistent use of omega-3 fatty acid concentrates or capsules within the 6 months prior to entry on the study
* Known sensitivity or allergy to fish oil or omega 3 fish products
* Pregnant or nursing women
* Subjects who cannot give an informed consent